NASDAQ: QURE CLASS ACTION NOTICE: Berger Montague Encourages uniQure N.V. (QURE) Investors to Inquire About a Securities Fraud Class Action

Core Viewpoint - A class action lawsuit has been filed against uniQure N.V. on behalf of investors who acquired its securities during the specified Class Period, alleging misrepresentation and failure to disclose critical information regarding the company's drug development process [1][3]. Company Overview - uniQure N.V. is a biotechnology company based in Amsterdam, focusing on gene therapies for severe diseases, including Huntington's disease [2]. Allegations - The lawsuit claims that uniQure misrepresented the approval status of its Pivotal Study for the drug AMT-130 and downplayed the potential need to delay its Biologics License Application (BLA) timeline due to additional studies [3]. Stock Impact - Following the disclosure on November 3, 2025, that the FDA did not accept the Phase I/II data as primary evidence for a BLA submission, uniQure's stock plummeted over 49%, dropping from $67.69 per share on October 31, 2025, to $34.29 per share on November 3, 2025 [4].